Glucosidase inhibitors for treatment of HIV-1 infection.
The HIV-1 envelope protein is a glycoprotein composed of 120 kD and 41 kD subunits. It contains 30-38 potential asparagine-linked glycosylation sites which have been shown to play a role in CD4 binding, virus uptake, and cytopathogenicity. Several inhibitors of oligosaccharide attachment or modification have been tested. An agent which inhibits glucosidases, N-butyl deoxynojirimycin was found to inhibit HIV-1 and SIVmac infectivity, and is currently in clinical trials.
Ratner
L
L
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000595:Amino Acid Sequence; D000998:Antiviral Agents / Q000627:therapeutic use*; D002240:Carbohydrate Sequence; D015686:Gene Products, env / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D006031:Glycosylation / Q000187:drug effects; D015497:HIV-1 / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D011499:Protein Processing, Post-Translational
D000998:Antiviral Agents; D015686:Gene Products, env; D005959:Glucosidases